FB102Beyond's analysis on FB1022026-07-27 — argenx's acquisition of Forte Biosciences adds a first-in-class anti-CD122 antibody to its immunology pipeline, expanding its therapeutic offeringsRecent news mentioning FB1022026-07-27 — argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB1022026-07-27 — argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology PipelineBrowse the full archive →